Hyderabad, February 19: Hyderabad-based Bharat Biotech on Saturday said its COVID-19 vaccine Covaxin will be evaluated as a vaccine candidate for the disease in the United States.

"Ocugen, Inc (NASDAQ: OCGN) announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on the Company's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States. Ocugen, Inc is co-developing Bharat Biotech's Covaxin vaccine candidate for COVID-19 in USA and Canada," reads Bharat Biotech's statement. More Than 175.03 Crore Coronavirus Vaccine Doses Administered In The Country So Far.

Earlier the Ministry of Health and Family Welfare had informed that Covaxin has been granted approval for emergency use in 13 countries as of January 31, 2022.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)